26-02-2009: Novacta Therapeutics Ltd announced the appointment of Dr David Pompliano to the Board of Directors. In addition to his role of non-executive director Dr. Pompliano will also provide strategic direction to Novacta’s R&D team and will hold the position of Chairman of the Scientific Advisory Board. The appointment of Dr Pompliano is part of the further development of Novacta’s therapeutic business.
Dr Pompliano was the former Vice President and Worldwide Basic Research Head of Antimicrobials at Merck, where he was responsible for discovery and early development strategy. Prior to that, Dr Pompliano was Vice President and Head of Biology for the Microbial Musculoskeletal and Proliferative Diseases Center for Excellence in Drug Discovery at GlaxoSmithKline, where he led a large and diverse group of biological scientists who, in collaboration with medicinal chemists, generated more than 25 small molecule development candidates, including novel structure antibacterials and antimalarials, target-specific cancer therapeutics and osteoporosis medicines. Three of these compounds, Tykerb, Altabax and Promacta, passed FDA review for new drug registration, and five other compounds are in Phase II clinical trials or beyond.
Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).Both single ascending dose and multiple ascending dose studies in a total o ... more
DSM BioSolutions announced that it has entered into an agreement with Novacta Biosystems Limited for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.
DSM has successfully completed the process development and commenced cGMP-man ... more
Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years.
“Following two very successful projects, we are excited to enter a third collaboration that co ... more
Novacta is a UK-based biotechnology company that specialises in the discovery and development of potential treatments for infectious diseases using a class of naturally occurring compounds called lantibiotics
Novacta's proprietary, patented technologies are in the fields of 'pathway engine ... more